Plug Power Inc (NASDAQ:PLUG), acquiring ReliOn is a small deal worth about $4 million. With the acquisition, Plug will get access to some of ReliOn’s patents and will own its own fuel cell stack technology. It’s surely a bit strange that Plug did not have this technology until now. Plug Power Inc (NASDAQ:PLUG), shares after opening at $7.08 moved to $7.44 on last trade day and at the end of the day closed at $7.32. Company price to sales ratio in past twelve months was calculated as 42.98 and price to cash ratio as 95.73. Plug Power Inc (NASDAQ:PLUG), showed a positive weekly performance of 3.98%.
Alpha Natural Resources, Inc. (NYSE:ANR)’s bonds have lost nearly 9.09% this year alone, which is the biggest, lost among other industry peers. The biggest challenge, on the other hand, lays on the fact that USD High Yield Corporate Index investors demand up to 9.67% points than other comparable treasuries to hold the company’s $800 million notes that are due in 2019. Alpha Natural Resources, Inc. (NYSE:ANR), shares advanced 1.38% in last trading session and ended the day on $4.40. Alpha Natural Resources, Inc. (NYSE:ANR), return on equity ratio is recorded as -24.70% and its return on assets is -9.00%. Alpha Natural Resources, Inc. (NYSE:ANR), yearly performance is -40.14%.
Arch Coal Inc (NYSE:ACI), was the target of some unusual options trading on Thursday. Investors acquired 24,045 put options on the stock, Analyst Ratings Net reports. This is an increase of 775% compared to the typical volume of 2,748 put options. Arch Coal Inc (NYSE:ACI), shares moved up 0.80% in last trading session and was closed at $5.01, while trading in range of $ 4.83 – 5.09. Arch Coal Inc (NYSE:ACI), year to date (YTD) performance is 12.84%.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s shares increased 6.05% to $7.09. ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD’s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), weekly performance is -0.41%. On last trading day company shares ended up $7.20. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), distance from 50-day simple moving average (SMA50) is -10.08%. Analysts mean target Price for the company is $9.06.